JND3229
JND3229 is a reversible inhibitor targeting the EGFR C797S mutation, demonstrating potent activity against resistant NSCLC cell lines (IC50 5.8 nM for L858R/T790M/C797S) . It shows robust anti-proliferative effects in vitro and effectively inhibits tumor growth in vivo, making it a valuable tool for oncology research, particularly in non-small cell lung cancer.
Product Specifications
CAS Number
2260886-64-2
Product Name Alternative
JND 3229, JND3229, JND-3229, EGFR
Field of Research
Cardiovascular Research, Signal Transduction
Purity
97.35% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.62 mM) ; DMSO:11.7 mg/mL (18.96 mM)
Smiles
CCC (=O) N[C@H]1CC[C@@H] (CC1) N1C (=O) N (Cc2cnc (Nc3ccc (N4CCN (C) CC4) c (C) c3) nc12) c1ccccc1Cl
Molecular Formula
C33H41ClN8O2
Molecular Weight
617.18
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD312 (EMR2, Epidermal Growth Factor-Like Module-Containing Mucin-Like Receptor 2, Epidermal Growth Factor Seven Transmembrane, EGF-TM7) (FITC)
